SM
DNA icon

SG3 Management’s Ginkgo Bioworks DNA Stock Holding History

SG3 Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,250
Closed -$119K – 338
2022
Q2 		$119K Sell
1,250
-1,500
-55% -$183K 0.01% 311
2022
Q1 		$443K Buy
2,750
+2,250
+450% +$438K 0.01% 628
2021
Q4 		$166K Buy
+500
New +$238K ﹤0.01% 837

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

SG3 Management's DNA Position: Q2 2022 in Review

SG3 Management sold out of Ginkgo Bioworks (DNA) in Q2 2022, closing a stake of 1,750 shares — an estimated $213K sold.

SG3 Management first reported a position in DNA in Q1 2022 and held it in 1 quarter. The position peaked at $282K in Q1 2022. 260 funds tracked by Wall St. Rank hold DNA as of Q2 2022.

  • SG3 Management reported no remaining Ginkgo Bioworks position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 1,750 Ginkgo Bioworks shares in Q2 2022, an estimated $213K.
  • SG3 Management first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 1 quarter.
  • SG3 Management's Ginkgo Bioworks position peaked at $282K in Q1 2022.
  • 260 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.